Progressive muscular atrophy (PMA) is clinically characterized solely by signs of lower motor neuron dysfunction, so patients with this condition are commonly excluded from ALS clinical trials.

Spinal muscular atrophy is a rare genetic disease characterized by a loss of motor neurons in the spinal cord and lower brain stem, resulting in severe, progressive muscle atrophy and weakness.